Alice S Mims

Trials

Studies that name Alice S Mims as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:30 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT05886049 · A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

  National Cancer Institute (NCI) · recruiting · Acute Myeloid Leukemia, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation · principal investigator
• Ph2
  NCT05401097 · IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

  Alice Mims · recruiting · Acute Myeloid Leukemia · principal investigator
• Ph1
  NCT04277442 · Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia

  National Cancer Institute (NCI) · completed · Acute Myeloid Leukemia · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 10:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Dual Targeting of Oncogenic Signaling and Immune Suppression in High-Risk T-ALL
  R01CA317674 · NCI · OHIO STATE UNIVERSITY · fiscal years 2026 · $511,944 awarded in 2026
  Same name and institution; not confirmed by an ID
• Understanding Treatment Response Patterns And Therapy Resistance In IDH-Mutant AML
  R01CA262496 · NCI · OHIO STATE UNIVERSITY · fiscal years 2022 to 2026 · $651,938 awarded in 2026
  Grant number is on one of their registry trials
• Targeting NAMPT in Acute Myeloid Leukemia
  R01CA223165 · NCI · OHIO STATE UNIVERSITY · fiscal years 2018 to 2022 · $461,498 awarded in 2022
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network
  UM1CA186712 · NCI · OHIO STATE UNIVERSITY · PI SUSANNE M ARNOLD, WILLIAM E. CARSON, Narendranath Epperla · fiscal years 2014 to 2026
  Named on NCT05886049, NCT04277442